TABLE 3.
QOPI Standards for Breast Cancer Care in the Molecular Profiling of Breast Cancer Study Cohort (n = 1,278)
| Country | Argentina | Brazil | Chile | Mexico | Uruguay | Total |
|---|---|---|---|---|---|---|
| QOPI standard, No./Total (%) | ||||||
| BR52a: complete staging for patients with invasive breast cancer (cancer stage, HER2, and ER/PR status) | 251/254 (98.8) | 267/284 (94.0) | 159/175 (90.8) | 391/455 (85.9) | 100/110 (90.9) | 1,168/1,278 (91.4) |
| BR53: combination chemotherapy received within 4 months of diagnosis by women younger than 70 years with AJCC stage IA (T1c) and IB-III ER-/PR-negative breast cancer | 26/36 (72.2) | 42/51 (82.3) | 22/25 (88.0) | 88/98 (89.8) | 11/11 (100) | 189/221 (85.5) |
| BR54: test for HER-2 overexpression or gene amplification | 252/254 (99.2) | 270/284 (95.1) | 161/175 (92.0) | 410/455 (90.1) | 103/110 (93.6) | 1,200/1,278 (93.9) |
| BR57 (also BR55): Appropriate treatment for patients with stage I (T1c)-III HER2-positive breast cancer | 39/44 (88.6) | 55/62 (88.7) | 9/27 (33.3) | 55/99 (55.5) | 9/14 (64.3) | 167/246 (67.9) |
| BR58 (also BR59): tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage IA (T1c) and IB-III ER-/PR-positive breast cancer | 64/183 (34.9) | 77/215 (35.8) | 31/128 (24.2) | 103/280 (36.8) | 40/81 (49.4) | 315/887 (35.5)a |
| BR58 by study arm—primary surgery arm, No./Total (%) | 38/88 (43.2) | 38/76 (50.0) | 25/64 (39.1) | 67/126 (53.2) | 34/49 (69.4) | 202/567 (35.6)a |
| BR58 by study arm—neoadjuvant arm, No./Total (%) | 26/68 (38.2) | 39/57 (68.4) | 6/35 (17.1) | 36/75 (29.2) | 6/15 (40.0) | 113/320 (35.3)a |
NOTE. This table only includes the QOPI's breast cancer–specific standards that could be evaluated in the MPBC study. The BR58 standard was also calculated by arm to show the by-country effect of neoadjuvancy in the delay of tamoxifen or AI administration.
Abbreviations: AJCC, American Joint Committee on Cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; QOPI, Quality Oncology Practice Initiative.
The denominator includes patients with no registry of treatment, with antihormonal therapies other than tamoxifen or AI, and/or with no date of treatment initiation. The total of patients who have a registered tamoxifen or AI adjuvant treatment at any moment is 653 of 887 for the whole cohort, 403 of 567 for the primary surgery arm and 250 of 320 for the neoadjuvant arm.